Want to see HRMY full AI Analyst Report?

Harmony Biosciences Holdings (HRMY) Price & Analysis

456 Followers

HRMY Stock Chart & Stats

$38.95

-$0.48(-1.34%)

At close: Jul 24 4:00 PM EDT

$38.95

-$0.48(-1.34%)

Day’s Range― - ―

52-Week Range$25.90 - $43.49

Previous CloseN/A

Volume585.34K

Average Volume (3M)1.00M

Market Cap

$2.23B

Enterprise Value$1.69B

Total Cash (Recent Filing)$667.79M

Total Debt (Recent Filing)$153.96M

Price to Earnings (P/E)12.2

Beta1.05

Next Earnings

Nov 04, 2026

EPS Estimate

1.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)3.13

Shares Outstanding58,236,393

10 Day Avg. Volume893,644

30 Day Avg. Volume1,002,079

Financial Highlights & Ratios

PEG Ratio1.74

Price to Book (P/B)2.47

Price to Sales (P/S)2.48

P/FCF Ratio6.18

Enterprise Value/Market Cap0.76

Enterprise Value/Revenue1.76

Enterprise Value/Gross Profit2.34

Enterprise Value/Ebitda6.12

Forecast

1Y Price Target

$46.00

Price Target Upside18.10% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

EPS Forecast (FY)3.95

Revenue Forecast (FY)$1.03B

Bulls Say, Bears Say

Bulls Say

Commercial GrowthStrong WAKIX demand, rising patient additions and more than 80% payer coverage support continued commercial expansion. Reiterated revenue guidance above $1 billion indicates management sees the growth trajectory as durable over the coming quarters.

Cash GenerationRobust operating and free cash flow demonstrates strong earnings quality and cash conversion. This internally generated liquidity gives Harmony flexibility to fund clinical development, commercial expansion and business development without relying heavily on external capital.

Pipeline And IPLayered intellectual-property protection helps preserve the core franchise, while BP-205, EPX-100, TEMPO and pitolisant lifecycle programs create opportunities beyond current WAKIX revenue. This broadens potential growth sources over the medium term.

Bears Say

Margin PressureHigher royalties are reducing gross margin relative to the prior year and could limit operating leverage as revenue scales. Persistent cost pressure would constrain profit growth and reduce the portion of commercial cash generation available for pipeline investment.

ANDA LitigationThe unresolved ANDA litigation creates uncertainty around the timing and durability of WAKIX exclusivity. An unfavorable outcome could accelerate competitive entry, pressure the franchise’s commercial economics and weaken visibility for the company’s principal revenue source.

Product ConcentrationEarnings remain heavily dependent on one U.S. marketed product, so patient demand, reimbursement and commercial execution for WAKIX have an outsized effect on results. Pipeline programs may diversify the business, but their contribution remains prospective.

Harmony Biosciences Holdings News

Harmony Biosciences initiated with a Buy at Ladenburg

Ladenburg initiated coverage of Harmony Biosciences (HRMY) with a Buy rating and $55 price target The firm says...

8d ago

HRMY

Mizuho positive on Harmony Biosciences CEO transition

After Harmony Biosciences (HRMY) announced that Peter Anastasiou, the company’s current COO, will become President, CEO and a...

11d ago

HRMY

Harmony Biosciences CEO Jeffrey Dayno to retire, Peter Anastasiou to succeed

Harmony Biosciences (HRMY) announced that, as part of the board of directors’ succession planning, Peter Anastasiou, former Harmony...

11d ago

HRMY

Harmony Biosciences price target raised to $42 from $39 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Harmony Biosciences (HRMY) to $42 from $39 and keeps a...

22d ago

HRMY

Harmony Biosciences management to meet with Oppenheimer

Meeting to be held in Denver on October 6 and in Houston on October 7 hosted by Oppenheimer....

22d ago

HRMY

Harmony Biosciences announces CEO transition and succession

An update from Harmony Biosciences Holdings ( ($HRMY) ) is now available. Harmony Biosciences announced on Oct. 12,...

10d ago

HRMY

Intuit downgraded, SolarEdge upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

BNS

DKS

Harmony Biosciences initiated with an Outperform at Wolfe Research

Wolfe Research analyst Rudy Li initiated coverage of Harmony Biosciences (HRMY) with an Outperform rating and $60 price...

2M ago

HRMY

Harmony Biosciences: Strengthening Core Business and Pipeline Support Unchanged $55 Price Target and Buy Rating

Harmony Biosciences Holdings, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio...

2M ago

HRMY

Harmony Biosciences price target raised to $34 from $29 at Truist

Truist analyst Danielle Brill raised the firm’s price target on Harmony Biosciences (HRMY) to $34 from $29 and...

3M ago

HRMY

Harmony Biosciences price target raised to $39 from $36 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Harmony Biosciences (HRMY) to $39 from $36 and keeps a...

3M ago

HRMY

Harmony Biosciences price target raised to $37 from $33 at UBS

UBS raised the firm’s price target on Harmony Biosciences (HRMY) to $37 from $33 and keeps a Neutral...

3M ago

HRMY

Harmony Biosciences Earnings Call Highlights Growth and Risks

Harmony Biosciences Holdings, Inc. (($HRMY)) has held its Q2 earnings call. Read on for the main highlights of...

3M ago

HRMY

Harmony Biosciences Price Target Raised to $50 on BP-205’s Strong Clinical Profile and Strategic Value

In a report released today, Ami Fadia from Needham maintained a Buy rating on Harmony Biosciences Holdings, with...

3M ago

HRMY

HRMY FAQ

What was Harmony Biosciences Holdings’s price range in the past 12 months?

Harmony Biosciences Holdings lowest stock price was $25.90 and its highest was $43.49 in the past 12 months.

What is Harmony Biosciences Holdings’s market cap?

Harmony Biosciences Holdings’s market cap is $2.23B.

When is Harmony Biosciences Holdings’s upcoming earnings report date?

Harmony Biosciences Holdings’s upcoming earnings report date is Nov 04, 2026 which is in 12 days.

How were Harmony Biosciences Holdings’s earnings last quarter?

Harmony Biosciences Holdings released its earnings results on Aug 04, 2026. The company reported $1.28 earnings per share for the quarter, beating the consensus estimate of $0.956 by $0.324.

Is Harmony Biosciences Holdings overvalued?

According to Wall Street analysts Harmony Biosciences Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Harmony Biosciences Holdings pay dividends?

Harmony Biosciences Holdings does not currently pay dividends.

What is Harmony Biosciences Holdings’s EPS estimate?

Harmony Biosciences Holdings’s EPS estimate is 1.11.

How many shares outstanding does Harmony Biosciences Holdings have?

Harmony Biosciences Holdings has 58,236,393 shares outstanding.

What happened to Harmony Biosciences Holdings’s price movement after its last earnings report?

Harmony Biosciences Holdings reported an EPS of $1.28 in its last earnings report, beating expectations of $0.956. Following the earnings report the stock price went up 8.933%.

Which hedge fund is a major shareholder of Harmony Biosciences Holdings?

Currently, no hedge funds are holding shares in HRMY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Harmony Biosciences Holdings Stock Smart Score

Outperform

Fundamentals

Return on Equity

20.06%

Trailing 12-Months

Asset Growth

23.92%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Harmony Biosciences Holdings

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

Harmony Biosciences Holdings (HRMY) Earnings & Revenues

Historic Earnings Reports

HRMY Company Deck

HRMY Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed a predominantly positive commercial and early clinical story: record revenue growth, accelerating patient adds, improved profitability, a strong cash position, and encouraging Phase I PK/safety data for BP‑205 that support once‑daily dosing and potency. Near‑term risks include higher COGS driven by new royalties, pending MAD safety data (insomnia and polyuria reported as transient signals), active ANDA litigation, and enrollment/timing uncertainties for some trials. On balance, the company demonstrated strong execution on revenue and commercialization while delivering promising early BP‑205 data and maintaining ample capital to pursue business development and R&D; remaining near‑term uncertainty centers on upcoming MAD and efficacy readouts and legal outcomes.View all HRMY earnings summaries

HRMY Stock 12 Month Forecast

Average Price Target

$46.00

▲(18.10% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","34":"$34","43":"$43","52":"$52","61":"$61"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$46.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,34,43,52,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.57,41.14153846153846,42.713076923076926,44.284615384615385,45.856153846153845,47.42769230769231,48.99923076923077,50.57076923076923,52.142307692307696,53.713846153846156,55.285384615384615,56.85692307692308,58.42846153846154,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.57,40.06461538461539,40.55923076923077,41.05384615384615,41.54846153846154,42.043076923076924,42.53769230769231,43.03230769230769,43.526923076923076,44.02153846153846,44.51615384615385,45.01076923076923,45.505384615384614,{"y":46,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.57,38.83384615384615,38.097692307692306,37.36153846153846,36.62538461538462,35.88923076923077,35.153076923076924,34.41692307692308,33.68076923076923,32.94461538461538,32.208461538461535,31.472307692307695,30.736153846153847,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.92,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.84,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.96,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.83,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.81,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.24,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.25,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.57,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >